Dr. Petrylak Explains Prostate Cancer Clinical Trial Difficulties

Video

In Partnership With:

Daniel P. Petrylak, MD, from Columbia University Medical Center Explains the Difficulties Facing During Prostate Cancer Clinical Trials

Daniel P. Petrylak, MD, Professor of Medicine, Program Director of the Genitourinary Oncology Section in the Division of Hematology/Oncology and Co-Leader, Prostate Cancer in the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center Explains the Difficulties Facing During Prostate Cancer Clinical Trials

Related Videos
Jean L. Koff, MD, MS
Rohan Garje, MD
Debu Tripathy, MD
Benjamin Garmezy, MD
Jeffrey P. Townsend, PhD
Michael Iglesia, MD, PhD
Jean L. Koff, MD, MS
Rohan Garje, MD
Nan Chen, MD
Sundar Jagannath, MBBS
Related Content
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

May 6th 2024
Article
Neeraj Agarwal, MD

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

July 17th 2023
Podcast
Stephen J. Freedland, MD

Enzalutamide Improves Undetectable PSA Rates Alone and With Leuprolide in Nonmetastatic CSPC

May 4th 2024
Article
Andrew J. Armstrong, MD, MSc

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

June 15th 2023
Podcast
prostate cancer

Prior Abiraterone Strengthens Outcomes With Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC

May 3rd 2024
Article
18F-PSMA-1007 PET/CT in Prostate Cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

18F-PSMA-1007 PET/CT Provides Staging Benefit Over MRI in Prostate Cancer

May 3rd 2024
Article